

DECLARE TRIAL

Dapagliflozin Effect on Cardiovascular Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patient with Type 2 Diabetes

The study population will include those who meet the following inclusion/exclusion criteria, some of which are:

Inclusion Criteria:

- Provision of informed consent prior to any study specific procedures
- Female or male aged ≥ 40 years
- Diagnosed with Type 2 Diabetes
- High Risk for Cardiovascular events

Exclusion Criteria:

- Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time
- Chronic cystitis and/or recurrent urinary tract infections
- Pregnant or breast-feeding patients

To inquire if you are eligible for this study or hear more about it, please contact:

**Pentucket Medical Associates
Clinical Research Office
(978) 469-5494**